Quantcast

Research and Markets: Diabetes – Prevalence of Diabetes Set to Increase From 177m Worldwide to 370m By 2030

November 29, 2004

Research and Markets (http://www.researchandmarkets.com/reports/c10220) has announced the addition of Diabetes to their offering

A diabetes epidemic is under way. According to the World Health Organization (WHO), an estimated 30m people worldwide had some form of diabetes in 1985; by 2000, the number had increased to 177m. WHO projections suggest that the number of people suffering from the disease will increase to some 370m by 2030.

This report focuses on 10 key countries, providing coverage of the market in North America, Europe, Japan and Latin America. These countries accounted for 86% of the global market in 2002. The largest market by a huge margin is the US, which, at close to $7bn in 2002, was well over five times larger than the second-ranked market, Japan. Although 2002 was a relatively poor year in the US (with little increase in overall sales), the American market has grown rapidly in recent years, to account for 57% of world sales, compared with less than 50% in 1998. In contrast, relatively steady sales increases in Japan and third-ranked Germany have resulted in a loss of market share for these countries, in global terms. This has also happened elsewhere in Europe, such as in France, Italy and Spain. In contrast, the markets in Canada and Mexico have expanded rapidly.

The costs involved in the care and management of diabetes are increasing rapidly. The WHO estimates that, on a global basis, 4-5% of health budgets is spent on diabetes and diabetes-related illnesses. As discussed in this report, a person with diabetes incurs medical costs that are two to five times higher than those of a person without diabetes. Diabetes incurs considerable indirect costs due to the number of patients who may not be able to continue working or work as effectively as they could before the onset of their condition. Factoring in such indirect costs, the American Diabetes Association calculated that the total cost of diabetes in the US was $132bn in 2002.

The second largest class, human insulin/analogues, has also shown strong growth, at 14% per year to just over $4bn in 2002, cannibalising sales of animal insulins, the market for which contracted by almost a quarter each year, on a CAGR basis. The animal insulin class is now very small, with global sales of only $50m in 2002. Other drugs for diabetes (Class A10X) showed virtually no movement over the period reviewed in this report, to stand at $266m in 2002.

The diabetes market is concentrated in the hands of six key players, which between them account for three-quarters of sales. In 2002, the market was headed by Lilly, with sales of $2bn and a 16% share. Second-ranked Takeda made sales of over $1.8bn, to account for almost 15%. This put the increasingly focused Japanese pharmaceutical company just ahead of Novo Nordisk, which is something of a specialist in the diabetes market. The next three companies in the rankings were the major multinationals, GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMS) and Aventis.

Key Findings:

— Currently 4-5% of health budgets is spent on diabetes and diabetes-related illness: this expenditure is also forecast to increase rapidly

— In the short term, recently launched oral antidiabetics, as well as fast and long acting insulins, will drive the market

— There is also a rapid increase in the number of children presenting with the disease

— The market formed by such products totalled over $12bn in 2002

— With sales of $7bn, the US is the dominant market, ahead of Japan and Germany

— Six companies account for 75% of global diabetes sales

— In oral antidiabetics, as well as in insulins, marketers of innovative products face increasing competition from lower-priced generics and, in Europe, parallel imports

The prevalence of diabetes will increase from 177m worldwide to 370m by 2030. But the market faces unprecedented change in terms of:

— Obesity driving market growth

— Intense competition from effective generics such as metformin and the sulphonylureas

— Uncertain performance of glitazones in non-US markets

— Impact of oral antidiabetics and oral or inhaled insulins

— Development of drugs targeting specific symptoms

— Payees’ increasing resistance to rapidly increasing healthcare costs

TABLE OF CONTENTS

EXECUTIVE SUMMARY 1

1 DISEASE OVERVIEW 10

2 GLOBAL EPIDEMIOLOGY 21

3 REGIONAL AND NATIONAL EPIDEMIOLOGY 26

4 DIABETIC DRUG CLASSES 32

5 LEADING PRODUCTS IN THE GLOBAL MARKET 42

6 LEADING GLOBAL MANUFACTURERS 77

7 OVERVIEW OF NATIONAL DIABETES MARKETS 120

8 THE BRAZILIAN MARKET 125

9 THE CANADIAN MARKET 135

10 THE FRENCH MARKET 144

11 THE GERMAN MARKET 153

12 THE ITALIAN MARKET 165

13 THE JAPANESE MARKET 173

14 THE MEXICAN MARKET 185

15 THE SPANISH MARKET 193

16 THE UK MARKET 201

17 THE US MARKET 210

18 RESEARCH AND DEVELOPMENT 220

19 THE FUTURE OF NATIONAL DIABETES MARKETS 265

20 OPINIONS ON THE FUTURE OF DIABETES TREATMENT 288

For more information visit http://www.researchandmarkets.com/reports/c10220




comments powered by Disqus